TELE:LSE:LSE-SSgA SPDR ETFs Europe II Public Limited Company - SPDR MSCI Europe Telecommunications UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 68.3

Change

-0.17 (-0.25)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-27 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

N/A

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

N/A

USD 562.96B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 562.96B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

N/A

USD 266.08B
0QZO:LSE 0QZO

N/A

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

N/A

USD 239.13B
0QZ3:LSE Qualcomm Inc.

N/A

USD 202.26B
0R24:LSE Intel Corp.

N/A

USD 196.14B

ETFs Containing TELE:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.26% 72% C 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.26% 71% C- 71% C-
Trailing 12 Months  
Capital Gain 15.26% 72% C 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.26% 71% C- 71% C-
Trailing 5 Years  
Capital Gain 17.19% 48% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.19% 44% F 57% F
Average Annual (5 Year Horizon)  
Capital Gain 7.08% 52% F 59% D-
Dividend Return 7.08% 52% F 58% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.51% 62% D 77% C+
Risk Adjusted Return 61.50% 63% D 77% C+
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike